MedPath

Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats

Phase 4
Not yet recruiting
Conditions
Rhabdomyolysis
Interventions
Diagnostic Test: iron
Diagnostic Test: MDA, TAC, and GSH
Diagnostic Test: Nrf2
Diagnostic Test: AMPK
Diagnostic Test: HO-1
Registration Number
NCT06491394
Lead Sponsor
Aswan University Hospital
Brief Summary

This study focuses on detecting the possible beneficial effect of Lactoferrin (Lf) administration on the kidney and the heart of glycerol-induced rhabdomyolysis (RM) in rats and its relation to ferroptosis and AMPK/Nrf2/ HO-1 signalling pathway. The main questions it aims to answer are:

1. Is Lf administration 30 min. before or after RM induction in rats beneficial to kidneys and heart?

2. When administered to glycerol-induced rats, does Lf act by upregulating the AMPK/Nrf2/ HO-1 signalling pathway and inhibiting ferroptosis?

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Male
Target Recruitment
24
Inclusion Criteria
  • • Twenty-four healthy male Wistar Albino rats weighing from 250 to 300 g
Exclusion Criteria
  • No exclusion criteria as this study is used to detect effects of drugs on experimental rats.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlironNormal saline will be administered once to rats intramuscularly (10 mL/kg).
ControlMDA, TAC, and GSHNormal saline will be administered once to rats intramuscularly (10 mL/kg).
ControlNrf2Normal saline will be administered once to rats intramuscularly (10 mL/kg).
ControlAMPKNormal saline will be administered once to rats intramuscularly (10 mL/kg).
ControlHO-1Normal saline will be administered once to rats intramuscularly (10 mL/kg).
RMironA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and normal saline (4ml/kg) will be administered by gavage.
RMMDA, TAC, and GSHA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and normal saline (4ml/kg) will be administered by gavage.
RMNrf2A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and normal saline (4ml/kg) will be administered by gavage.
RMAMPKA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and normal saline (4ml/kg) will be administered by gavage.
RMHO-1A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and normal saline (4ml/kg) will be administered by gavage.
Lf-RMironA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. before RM induction
Lf-RMMDA, TAC, and GSHA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. before RM induction
Lf-RMNrf2A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. before RM induction
Lf-RMAMPKA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. before RM induction
Lf-RMHO-1A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. before RM induction
RM-LfironA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
RM-LfMDA, TAC, and GSHA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
RM-LfNrf2A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
RM-LfAMPKA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
RM-LfHO-1A single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
RMglycerinA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and normal saline (4ml/kg) will be administered by gavage.
Lf-RMLactoferrinA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. before RM induction
Lf-RMglycerinA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. before RM induction
RM-LfLactoferrinA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
RM-LfglycerinA single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation and Lf (1000 mg/kg in normal saline, volume 4 mL/kg) will be administered by gavage 30 min. after RM induction.
Primary Outcome Measures
NameTimeMethod
AMPK levels2 months

AMPK levels in kidney and heart tissue homogenate

HO-1 levels2 months

HO-1 levels in kidney and heart tissue homogenate

Nrf2 expression2 months

Nrf2 expression in heart and kidney tissues

Secondary Outcome Measures
NameTimeMethod
GSH levels2 months

GSH levels in heart and kidney tissue homogenate

TAC levels2 months

TAC levels in heart and kidney tissue homogenate

MDA levels2 months

MDA levels in heart and kidney tissue homogenate

iron levels2 months

Iron levels in heart and kidney tissue homogenate

© Copyright 2025. All Rights Reserved by MedPath